MDL | - |
---|---|
Molecular Weight | 1275.46 |
Molecular Formula | C57H97F3N14O15 |
SMILES | - |
Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL. Gap19 TFA is not blocking GJ channels or Cx40/pannexin-1 hemichannels. Gap19 TFA has protective effects against myocardial [1] [2] .
Cx43 Hemichannel [1]
Gap19 TFA (250 μM; for 30 min ) decreases mitochondrial potassium uptake
[1]
.
Gap19 TFA (400 μM) inhibits unitary hemichannel currents in HeLa-Cx43 cells
[2]
.
Gap19 TFA (100 μM) inhibits hemichannel unitary currents in ventricular cardiomyocytes
[2]
.
Gap19 TFA (250 μM, 30 min) protects against myocardial ischemia/reperfusion injury in vitro and in vivo
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Gap19 TFA (iv; 25 mg/kg; 10 min before ligation) significantly reduces the infarct size by approximately one-fifth
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | C57/BL6 mice [2] |
Dosage: | 25 mg/kg |
Administration: | IV; 10 min before ligation |
Result: | Significantly reduced the infarct size by approximately one-fifth. |
Solid
Room temperature in continental US; may vary elsewhere.
Sealed storage, away from moisture
Powder | -80°C | 2 years |
---|---|---|
-20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
DMSO : 100 mg/mL ( 78.40 mM ; Need ultrasonic)
H 2 O : 100 mg/mL ( 78.40 mM ; Need ultrasonic)
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 0.7840 mL | 3.9202 mL | 7.8403 mL |
5 mM | 0.1568 mL | 0.7840 mL | 1.5681 mL |
10 mM | 0.0784 mL | 0.3920 mL | 0.7840 mL |
Add each solvent one by one: PBS
Solubility: 100 mg/mL (78.40 mM); Clear solution; Need ultrasonic